Abstract
Purpose
Azidothymidine (AZT, zidovudine) has been shown to reverse cisplatin resistance in cell culture. This phase I study was performed to determine the maximally tolerated dose (MTD) and dose-limiting toxicities of AZT when administered by continuous intravenous infusion in combination with cisplatin (CDDP), and to evaluate the pharmacokinetics of AZT in this setting.
Patients and methods
Entered in the study were 61 patients with advanced, histologically confirmed malignancies which were unresponsive to or for which no "standard" chemotherapeutic regimen existed. AZT was administered as a 72-h infusion on days 1–3 and 14–16 of a 28-day cycle at dose levels from 400 through 14,364 mg/m2 per day. CDDP at dose levels of 30, 45, or 60 mg/m2 was administered at hour 36 of each AZT infusion. The plasma pharmacokinetics of AZT were determined in patients treated at representative dose levels.
Results
Of the 61 patients who completed 125 courses of therapy, 21 had stable disease for a median of four cycles (range two to eight), 33 progressed on therapy, and 7 were not assessable for response. The major observed toxicity was myelosuppression. The MTD of AZT was 8135 mg/m2 per day when administered on this schedule. Escalation of CDDP did not result in additive toxicity. The mean steady-state level of AZT at the MTD was 44 μM (range 35–51 μM).
Conclusions
Steady-state concentrations of AZT increased with dose. The plasma levels achieved at the MTD exceeded those required for drug resistance reversal in vitro. The administration of CDDP had no effect on AZT steady-state levels. The dose-limiting toxicity of this drug combination is myelosuppression. AZT may be useful in further studies utilizing combination therapy to achieve increased chemotherapy effectiveness.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beitz JG, Damowski JW, Cummings FJ, Browne MJ, Clark JW, Bigley JW, Weitberg AB (1995) Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. Cancer Invest 13:464–469
Browne MJ, Beitz J, Clark JW, Cummings FJ, Weitberg A, Murray C, Darnowski JW (1993) A phase I study of zidovudine (AZT) combined with methotrexate in patients with advanced cancer (meeting abstract). Proc ASCO 12:A451
Brunetti I, Darnowski JW, Falcone A, Johnson KA, Calabresi P (1989) Azidothymidine enhances fluorouracil and methotrexate antitumor and therapeutic activity. Proc Am Assoc Cancer Res 30:A2369
Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW (1990) 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res 50:4026–4031
Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996) Phase II study of 5-fluorouracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 122:554–558
DeLap R, Swain S, Ong D, Rosen N, Bodurian E, Steakley C, Nazzaro D, King D, Santore G (1991) A phase I study of zidovudine (azt), leucovorin (lv), and fluorouracil (fu) in patients with advanced cancer. Proc ASCO 10:A295
Eastman A (1985) Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 24:5027–5032
Good SS, Reynolds DJ, de Miranda P (1988) Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr 431:123–133
Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253
Paietta E, Racevskis J, Heavey C, Lichtenstein A, Thomas D, Wiernik PH (1993) Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Proc ASCO 12:302
Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, Calabresi P (1992) High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 70:2929–2934
Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303-2316
Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J (1989) Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9:1301–1312
Scanlon KJ, Kashani-Sabet M, Sowers LC (1989) Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1:269–275
Scanlon KJ, Funato T, Pezeshki B, Tone T, Sowers LC (1990) Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun 2:339–343
Yarchoan R, Mitsuya H, Myers CE, Broder S (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 321:726–738
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented in part at the Annual Meeting of the American Society of Clinical Oncology and reported in Proc ASCO 1994;1:146. The work was supported by NCI Cancer Center Core Grant CA 33572, and Burroughs Wellcome.
Rights and permissions
About this article
Cite this article
Morgan, R.J., Newman, E.M., Sowers, L. et al. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother Pharmacol 51, 459–464 (2003). https://doi.org/10.1007/s00280-003-0605-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0605-0